Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 autologous CD19 CAR-T study in relapsed/refractory CD19-positive malignancies
MOH_2026-03-05_015700Phase 2Not yet recruiting
- Sponsor
- פרופ' משה ישורון
- Start
- Sep 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial of RMC CD19 CAR-T in lymphoma (3 arms), sponsored by פרופ' משה ישורון. Primary endpoints: Incidence and severity of cytokine release syndrome, Incidence and severity of immune effector cell-associated neurotoxicity syndrome and 3 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
RMC CD19 CAR-T
03
Conditions
lymphoma
Beyond the preview
Go deeper on MOH_2026-03-05_015700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-05_015700.